Randomized Trialhigh evidence
Apitegromab for lean mass preservation during tirzepatide-induced weight loss: a randomized, double-blind, placebo-controlled phase 2 trial.
Nature medicine·June 8, 2026·PMID 42260100
Why it mattersGLP-1–based weight loss often includes significant lean mass loss, which may impair metabolic health and physical function. This study provides proof-of-concept that myostatin inhibition can selectively preserve muscle during pharmacotherapy-induced weight loss.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled